Acute reduction of TxA2 platelet binding sites after in vivo administration of a TxA2 receptor inhibitor

P. A. Modesti, A. Colella, I. Cecioni, G. F. Gensini, R. Abbate, G. G. Neri Serneri

Research output: Contribution to journalArticlepeer-review


Picotamide has been shown to interfere competitively with the thromboxane A2 (TxA2) platelet receptor. In the present study the effect of in vivo administration of picotamide on TxA2 human platelet receptors was investigated in 10 healthy subjects. Picotamide (300 mg x 3 daily) or placebo were administered in a double-blind, crossover, placebo controlled study, each treatment lasting 1 week with a 2 week interval period. TxA2 receptors were investigated by a direct radioligand binding assay method employing [1251]-PTA-OH as labelled ligand. Platelet studies were performed on the first day of treatment immediately before and 2, 4 and 8 h after the ingestion of the drug. The effects of chronic administration were assessed on the seventh day. Two and 4 h after the administration of picotamide 300 mg orally platelet TxA2 receptors were significantly reduced from 1366 ± 237 to 957 ± 221 (P <0.05) and 753 ± 119 receptors/platelet (mean ± s.d.) (P <0.03). After 8 h platelet receptor population was restored (1362 ± 324, NS). The same pattern was observed after 7 days of treatment. Thus picotamide seems to induce a short lasting down regulation of platelet TxA2 receptors.

Original languageEnglish
Pages (from-to)439-443
Number of pages5
JournalBritish Journal of Clinical Pharmacology
Issue number4
Publication statusPublished - 1991


  • picotamide
  • platelets
  • thromboxane A

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Acute reduction of TxA2 platelet binding sites after in vivo administration of a TxA2 receptor inhibitor'. Together they form a unique fingerprint.

Cite this